MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31, TBPH has $472,313K in assets. $288,101K in cash and cash equivalents.

Balance Sheets Overview

Current Ratio
1314.35%
Quick Ratio
1314.35%
Cash Ratio
906.69%
Unit: Thousand (K) dollars
Assets Breakdown
    • Cash and cash equivalents
    • Short-term marketable securities
    • Other assets
    • Others
Liabilities Breakdown
    • Additional paid-in capital
    • Accumulated deficit
    • Unrecognized tax benefits
    • Others

Balance Sheets
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Cash and cash equivalents
288,101 167,806 174,773 281,927
Short-term marketable securities
106,565 147,551 154,907 56,877
Receivables from collaborative arrangements
15,584 45,539 18,267 21,919
Receivables from milestones and royalty assets
-50,000 --
Other prepaid and current assets
7,384 7,564 6,750 5,571
Total current assets
417,634 418,460 354,697 366,294
Long-term marketable securities
-11,128 3,029 -
Property and equipment, net
5,539 5,895 6,257 6,641
Operating lease assets
23,001 24,371 25,450 26,493
Restricted cash
836 836 836 836
Other assets
25,303 24,880 25,191 25,771
Total assets
472,313 485,570 415,460 426,035
Accounts payable
1,100 2,568 2,213 1,675
Accrued personnel-related expenses
8,730 12,592 10,330 7,259
Accrued clinical and development expenses
2,396 3,373 5,842 3,783
Accrued general and administrative expenses
2,522 2,052 2,699 2,459
Operating lease liabilities
10,752 10,945 10,914 10,896
Income tax payable
5,287 5,287 4,074 26,696
Other accrued liabilities
988 1,485 1,335 1,865
Total current liabilities
31,775 38,302 37,407 54,633
Long-term operating lease liabilities
29,752 31,758 33,681 35,561
Unrecognized tax benefits
--79,165 77,805
Future royalty payment contingency
32,795 32,795 32,213 31,640
Unrecognized tax benefits
87,153 85,679 --
Other long-term liabilities
244 313 313 1,548
Ordinary shares, 0.00001 par value per share 200,000 shares authorized 51,515 and 51,069 shares issued and outstanding at march 31, 2026 and december 31, 2025, respectively
1 1 1 1
Additional paid-in capital
1,155,215 1,156,288 1,153,299 1,149,123
Accumulated other comprehensive income
-62 61 32 -10
Accumulated deficit
-864,560 -859,627 -920,651 -924,266
Total shareholders' equity
290,594 296,723 232,681 224,848
Total liabilities and shareholders' equity
472,313 485,570 415,460 426,035
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Cash and cashequivalents$288,101K Short-term marketablesecurities$106,565K Receivables fromcollaborative arrangements$15,584K Other prepaid andcurrent assets$7,384K Total current assets$417,634K Other assets$25,303K Operating lease assets$23,001K Property and equipment,net$5,539K Restricted cash$836K Total assets$472,313K Total liabilities andshareholders' equity$472,313K Total shareholders'equity$290,594K Unrecognized tax benefits$87,153K Future royalty paymentcontingency$32,795K Total currentliabilities$31,775K Long-term operating leaseliabilities$29,752K Other long-termliabilities$244K Accumulated deficit-$864,560K Accumulated othercomprehensive income-$62K Additional paid-in capital$1,155,215K Operating leaseliabilities$10,752K Accruedpersonnel-related expenses$8,730K Income tax payable$5,287K Accrued general andadministrative expenses$2,522K Accrued clinical anddevelopment expenses$2,396K Accounts payable$1,100K Other accruedliabilities$988K Ordinary shares, 0.00001par value per share...$1K

Theravance Biopharma, Inc. (TBPH)

Theravance Biopharma, Inc. (TBPH)